Floatz logo

Idelalisib

Follicular Lymphoma, Mantle Cell Lymphoma

Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Follicular Lymphoma, Mantle Cell Lymphoma cohort.

Asset / SponsorPhaseRating
s 55746
Novartis Pharmaceuticals
Phase 1CC

Same molecule, other indications

Idelalisib is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
59 / 100
View asset →
lymphoplasmacytic lymphomaDormant
B
Indicative ·
57 / 100
View asset →
marginal zone lymphomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →